XML 21 R10.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 3 - Earnings Per Share ("EPS")
 9 Months Ended
Jan. 29, 2022
Notes to Financial Statements  
Earnings Per Share [Text Block]

Note 3. Earnings Per Share ("EPS")

 

The following is a reconciliation of the net income and common share amounts used in the calculation of basic and diluted EPS for the three and nine months ended January 29, 2022 and January 30, 2021:

 

  

Net (loss) income

  

Shares

  

Per share (loss) income

 

For the three months ended January 29, 2022

            

Basic (loss) earnings per share

 $(4,350)  45,223  $(0.10)

Dilution associated with stock compensation plans

  —   —   — 

Diluted (loss) earnings per share

 $(4,350)  45,223  $(0.10)

For the three months ended January 30, 2021

            

Basic (loss) earnings per share

 $(214)  45,064  $(0.00)

Dilution associated with stock compensation plans

  —   —   — 

Diluted (loss) earnings per share

 $(214)  45,064  $(0.00)

For the nine months ended January 29, 2022

            

Basic earnings per share

 $1,709   45,263  $0.04 

Dilution associated with stock compensation plans

  —   179   — 

Diluted earnings per share

 $1,709   45,442  $0.04 

For the nine months ended January 30, 2021

            

Basic earnings per share

 $10,669   44,908  $0.24 

Dilution associated with stock compensation plans

  —   153   — 

Diluted earnings per share

 $10,669   45,061  $0.24 

 

Options outstanding to purchase 2,216 shares of common stock with a weighted average exercise price of $8.17 for the three months ended January 29, 2022 and 2,337 shares of common stock with a weighted average exercise price of $8.70 for the three months ended January 30, 2021 were not included in the computation of diluted earnings per share because the effects would be anti-dilutive.

 

Options outstanding to purchase 1,857 shares of common stock with a weighted average exercise price of $9.26 for the nine months ended January 29, 2022 and 2,268 shares of common stock with a weighted average exercise price of $9.29 for the nine months ended January 30, 2021 were not included in the computation of diluted earnings per share because the effects would be anti-dilutive.